Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

Abstract Background Glatiramer acetate (GA) is one of the first therapies approved for multiple sclerosis (MS). We prospectively included and monitored drug-naïve and pre-treated MS patients who had been prescribed GA for 1 year, to investigate reasons for GA prescription, its effectiveness and safe...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Chiara Zecca, Giulio Disanto, Rosaria Sacco, Gianna C. Riccitelli, Claudio Gobbi
Формат: Artigo
Язык:Inglês
Опубликовано: BMC 2019-07-01
Серии:BMC Neurology
Предметы:
CIS
GA
Glatiramer acetate
Multiple sclerosis
Relapsing remitting
Therapy
Online-ссылка:http://link.springer.com/article/10.1186/s12883-019-1383-6
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы